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Abstract
Chronic hepatitis C virus (HCV) infection is the most common cause of end-stage liver disease, often leading to liver
transplantation, in which case circulating virions typically infect the transplanted liver within hours and viral concentrations
can quickly exceed pre-transplant levels. MBL-HCV1 is a fully human monoclonal antibody recognizing a linear epitope of
the HCV E2 envelope glycoprotein (amino acids 412–423). The ability of MBL-HCV1 to prevent HCV recurrence after liver
transplantation was investigated in a phase 2 randomized clinical trial evaluating six MBL-HCV1-treated subjects and five
placebo-treated subjects. MBL-HCV1 treatment significantly delayed time to viral rebound compared with placebo
treatment. Here we report results from high-throughput sequencing on the serum of each of the eleven enrolled subjects
prior to liver transplantation and after viral rebound. We further sequenced the sera of the MBL-HCV1-treated subjects at
various interim time points to study the evolution of antibody-resistant viral variants. We detected mutations at one of two
positions within the antibody epitope—mutations of N at position 415 to D, K or S, or mutation of N at position 417 to S. It
has been previously reported that N415 is not glycosylated in the wild-type E2 protein, but N417S can lead to glycosylation
at position 415. Thus N415 is a key position for antibody recognition and the only routes we identified for viral escape,
within the constraints of HCV fitness in vivo, involve mutating or glycosylating this position. Evaluation of mutations along
the entire E1 and E2 proteins revealed additional positions that changed moderately before and after MBL-HCV1 treatment
for subsets of the six subjects, yet underscored the relative importance of position 415 in MBL-HCV1 resistance.
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Introduction
Chronic hepatitis C virus (HCV) infection is the most common
cause of end-stage liver disease leading to liver transplantation in
the United States [1]. Unfortunately, recurrence of hepatitis C
infection post-transplantation is nearly universal. While serum
HCV RNA levels initially decline with removal of the infected
liver, circulating virions infect the donor liver within hours and
viral concentrations increase rapidly in most patients, often
exceeding pre-transplant levels [2,3]. Recurrent HCV disease is
often more aggressive in the setting of post-transplant immuno-
suppression, with accelerated cirrhosis, increased risk of graft
failure, and death [4,5].
MBL-HCV1 is a novel fully human IgG1/kappa monoclonal
antibody (MAb) isolated from mice expressing human antibody
genes (Medarex, Inc., a wholly owned subsidiary of Bristol-Myers
Squibb). MBL-HCV1 binds a highly-conserved linear epitope of
the HCV E2 envelope glycoprotein (amino acids 412–423) and
neutralizes a broad range of genotypes in vitro [6]. MBL-HCV1 is
capable of preventing HCV infection in a chimpanzee model of
acute HCV [7]. Treatment of chronically-infected chimpanzees
with a single dose of MBL-HCV1 led to suppression of viral load
in a subset of animals for up to 14 days, with viral rebound
coinciding with the emergence of antibody-resistant virus.
Alterations at amino acid positions 415 (N415K and N415D)
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and 417 (N417S) within the MBL-HCV1 epitope dominated the
viral population in chimpanzees post-treatment [7].
The ability of MBL-HCV1 to prevent HCV recurrence after
liver transplantation is being investigated in clinical trials as
current treatment options are limited. In a phase 2 randomized,
placebo-controlled trial in this target population, treatment with
MBL-HCV1 significantly delayed median time to viral rebound
compared to placebo treatment [8]. The strong selective pressure
of this neutralizing antibody resulted in the emergence of MBL-
HCV1 resistance-associated variants (RAVs), as determined by
conventional cloning and Sanger sequencing methods in all
subjects receiving MAb monotherapy. The time to emergence of
detectable RAVs varied from 6 to 42 days and was associated with
a rebound in circulating viral titer.
In this article, we use high-throughput next generation
sequencing to investigate the presence of resistance mutations to
MAb pre-transplant and examine the post-transplant evolution of
HCV variants in the presence and absence of MBL-HCV1
antibody (SRA study accession number SRP037575).
Results
Analysis of HCV E1/E2 Variants at Time of Viral Rebound
Eleven enrolled subjects underwent liver transplantation in a
phase 2 clinical study (Table 1) [8]. Six subjects were randomized
to receive MBL-HCV1 (subjects A–F) and five subjects were
randomized to placebo (subjects G–K). To assess viral RNA
sequences found in serum samples obtained during the clinical
study, a high-throughput sequencing methodology was developed.
We initially applied high-throughput next generation sequencing
to samples obtained following 2 log10 viral rebound in MBL-
HCV1-treated subjects. For placebo subjects, samples obtained 7–
21 days post-transplantation were also sequenced. The frequencies
of amino acid alterations at the positions associated with resistance
to MBL-HCV1 neutralization were analyzed (Table 1).
Three of the MAb-treated subjects (Subjects A, B, and C)
experienced viral rebound of at least 2 log10 IU/ml by day 14
post-transplantation (Figure 1A–C). Subject A displayed a
mixture of N415D (78.5%) and N417S (20.5%) as the predom-
inant viral strains at the time of rebound. The rebounding
population found in subject B was dominated by the variant
N415K (97.1%). Subject C had a greater diversity at positions 415
and 417 than Subjects A or B at day 14, with N415D (56.0%),
N415K (2.6%), and N417S (12.7%) mixing with quasispecies
possessing wild-type epitope sequence (25.8%).
Three of the MAb-treated subjects experienced viral rebound
significantly later than day 14 (Figure 1D–F). Subject D
demonstrated the greatest suppression of HCV viremia following
MBL-HCV1 treatment. This subject’s viral load transiently fell
below the limit of detection and remained below the lower limit of
quantification of the HCV RNA assay through day 28. Viral load
rebounded 2 log10 IU/ml by day 42; however deep sequencing of
this serum sample failed for technical reasons. Deep sequencing of
the day 56 sample revealed a predominance of the N417S variant
(78.4%) and N415K (20.2%). Surprisingly, these two variants were
never detected in the same sequence read, indicating that either
variant was sufficient for viral escape. For subject E, a post-
rebound viral sample obtained on day 28 following transplantation
revealed a predominance of N415K (94.2%). Subject F did not
experience a 2 log10 IU/ml viral rebound until approximately 42
days post-transplantation and maintained wild-type virus (N415/
N417) at 34% at this time point. Resistance-associated mutations
N415S (27.1%), N415D (1.2%) and N417S (36.5%) were detected
by high-throughput sequencing. A previous ad hoc analysis of the
clinical data from the pharmacokinetic analysis showed no
correlation between the serum antibody concentration and the
time to viral rebound (data not shown).
For four of the five placebo-treated subjects (Subjects G-K),
high-throughput sequencing yielded wild type N415/N417
sequences at a frequency of .95% (Table 1, Figure 2).
Interestingly, subject J had a naturally occurring N417S variant
that dominated the viral population both pre- and post-transplan-
tation and demonstrated a unique pattern of viral rebound
compared to the other placebo subjects. Subject J did not rebound
to viral titers $10,000 IU/ml post-transplant, limiting the ability
to analyze post-transplant sequencing results in this subject.
Subject J did not have detectable circulating antibodies to the 412–
423 epitope.
Pre-Transplant Prevalence of Sequence Variation at
Amino Acids 415 and 417
With the emergence of four different viral variants following
treatment with MBL-HCV1 (N415K, N415D, N415S and
N417S), we next determined whether these variants were present
before transplantation in any of the 11 subjects. High-throughput
sequencing was performed on pre-transplantation serum samples
from all subjects. None of the MBL-HCV1-treated subjects
(Subjects A–F) had resistance-associated variants (Figure 1)
present above the detection threshold specified for each sample
(Table S1) pre-transplantation. Each placebo subject (Subjects G-
K) maintained the exact same amino acids at positions 415 and
417 E2 post-transplantation as they had exhibited pre-transplan-
tation (Table 1, Figure 2), suggesting that these positions are not
under selective pressure as the viral quasispecies adapt to the
newly transplanted liver.
Evolution of resistance-associated variants
Since daily serum samples were available for analysis from the
first week post-transplantation, high-throughput sequencing was
performed on serum samples obtained on Day 4 and Day 7 post-
transplantation from the three MBL-HCV1- treated subjects with
viral rebound occurring between days 7–14 (Subjects A, B, and C)
to explore the evolution of resistance-associated variants. The
amount of template in these samples was limited by the low viral
load at these early time points (Figure 1A–C), ranging from
1,010 IU/ml (Subject B, Day 7) to a maximum of 10,357 IU/ml
(Subject C, Day 4). On Day 4 post-transplantation, none of the
subjects had detectable levels of variants associated with resistance
to MBL-HCV1. By Day 7 post-transplant, neither Subject B nor
Subject C had detectable 415 or 417 variants, but Subject A had a
dominant population of RAVs (a mixture of N415D and N417S)
(data not shown). High-throughput sequencing of additional
samples obtained from Subject A during the first post-transplant
week revealed detectable resistance-associated variants on Day 3
(N417S, 6.9%), but not on Day 4 or Day 5 (data not shown). By
Day 6, however, resistance associated variants (N415D 26.5% and
N417S 53.7%) predominated the viral pool, even before the viral
load had appreciably increased in this subject).
Given the limited amount of starting template in serum samples
from MAb-treated subjects in the first week post-transplant,
multiple samples with viral titers ,3, 000 IU/ml were sequenced
a second time to assess the reproducibility of these results. For
subject A when library DNA from the Day 3 sample (1,930 IU/
ml), in which low-level RAV (N417S) were detected in the initial
analysis, was recreated with the same sets of primers and re-
sequenced, the N417S resistance-associated variant was no longer
detected. For the Day 4 sample (1,213 IU/ml), E1/E2 DNA
sequences were amplified from the original RNA preparation,
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subjected to 2 additional rounds of re-amplification with subject-
specific primers, and sequenced. This technique resulted in the
detection of 2 resistance-associated variants that predominated the
eventual viral rebound: N415D (1.9%) and N417S (17.4%). The
Day 5 sample was extracted from a new aliquot of serum from that
time point and amplified using the same techniques as the original
Day 5 sample. The repeat of sequencing from this timepoint
revealed N415D (13.9%) and N417S (2.8%) resistance-associated
variants that were not detected in the original sequencing run.
Finally, re-extraction of RNA and re-sequencing of the Day 6
timepoint yielded the same resistance associated variants as the
prior run, but at significantly lower frequencies compared with the
previous sequencing run (N415D 16.2% vs. 26.5% and N417S
19.0% vs. 53.7%).
These inconsistencies were also observed when low titer samples
from a second subject were re-sequenced. For Subject B, the Day 4
sample (2,704 IU/ml) was amplified from the same RNA
preparation and analyzed by high throughput sequencing.
Interestingly, there were detectable levels of N415K (7.82%), the
variant that eventually dominated the viral population at the time
of rebound, when this Day 4 sample was re-sequenced. However,
when the RNA from the Day 7 sample (1,010 IU/ml) from the
same subject (Subject B) was re-extracted, amplified, and re-
sequenced, there were no detectable 415 or 417 variants. These
findings demonstrate the limitations in the reproducibility of
detecting low-level variants contained within low-titer samples.
When serum samples with titers .10,000 IU/ml were subjected
to repeat sequencing however, the results were quite reproducible.
For example, subject A had a post-rebound viral titer of
35,530,988 IU/ml on Day 14 after transplantation. Two inde-
pendent amplification and sequencing runs yielded a frequencies
of 78.53–83.37% for the N415D variant and 15.54–20.47% for
the N417S variant.
Sequence evolution within the MBL-HCV1 epitope
Having analyzed positions 415 and 417, we also interrogated
the entire MBL-HCV1 epitope (amino acids 412–423) to assess
whether there were combinations of positions that likely contribute
to resistance. We analyzed the sequencing reads that covered the
entire epitope and identified the most abundant epitope sequences
in each sample. The frequency of each epitope sequence above the
detection limit is illustrated in Figure 1.
Consistent with the high conservation of this epitope, a majority
of reads translated to the sequence QLINTNGSWHIN on day 0
pre-transplantation in four of six MAb-treated subjects (89.0%,
87.8%, 90.8% and 84.4% for patients B, C, E and F, respectively).
Two of the MAb-treated subjects had a high frequency of the
I414V variant of this canonical sequence (26.2% in subject A and
91.3% in subject D). By the day of viral rebound, the pre-
transplant dominant epitope sequence dramatically declined in all
MAb-treated subjects. For four MAb-treated subjects (A, B, D,
and E), the epitope sequence that dominated pre-transplant was
below the detection threshold on the day of rebound. For subjects
C and F, the prevalence of the wild-type sequence dropped to
24.8% and 34.6% respectively.
The MAb-resistant epitope sequences contained only point
mutations at positions 415 or 417 with respect to the dominant
sequences pre-transplantation and all of the resistant variants were
obtained by mutating a single nucleotide. The most abundant
MAb-resistant variant differed among the subjects (I414V; N415D
for subject A, N415K for subjects B and E, N415D for subject C,
I414V; N417S for subject D, and N417S for subject F; Figure 1).
Table 1. Subject characteristics and resistance-associated variants at viral rebound.
Subject Treatment
Baseline IU/ml
(log10)
Study day sequenced
post-viral rebound
Estimated number of
input genomes
Position 415 amino
acid (%)
Position 417 amino
acid (%)
A MBL-HCV1 6.7 14 2,664,824 D (78.5) N (78.8)
N (20.8) S (20.5)
B MBL-HCV1 6.1 14 27,214 K (97.1) N (99.0)
N (1.7)
C MBL-HCV1 7.2 14 32,037 D (56.0) N (85.6)
N (39.7) S (12.7)
K (2.6)
D MBL-HCV1 4.5 56 48,210 N (78.8) S (78.4)
K (20.2) N (21.1)
E MBL-HCV1 6.0 28 32,196 K (94.2) N (97.9)
N (2.7)
F MBL-HCV1 6.1 42 251,910 N (69.5) N (61.5)
S (27.1) S (36.5)
D (1.2)
G Placebo 6.6 7 1,698,789 N (99.1) N (98.8)
H Placebo 5.5 7 25,752 N (95.9) N (96.7)
I Placebo 6.0 21 575,572 N (98.6) N (99.1)
J Placebo 5.1 21* 56 N (99.0) S (98.7)
K Placebo 5.6 7 2,434,095 N (98.9) N (99.3)
* - Viral titer ,10,000 IU/ml at this time point.
Bold and underlined text represents sequence that diverges from the consensus.
doi:10.1371/journal.pone.0100325.t001
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Nonetheless, a glycosylation site is maintained in the variant, with
the ‘‘N-X-S’’ motif starting at either positions 415 or 417
(Figure 1G). A mutation at position 415 (from unglycosylated
N to D, K, S, or glycosylated N) appears required for evasion of
MBL-HCV1 neutralization. In comparison, none of these MAb-
resistant epitope sequences emerged post-transplant in the subjects
treated with placebo (Figure 2).
Sequence evolution outside the MBL-HCV1 epitope
We then expanded our analysis outside the MBL-HCV1
epitope by scanning the entire length of the deeply-sequenced
E1/E2 regions to identify other amino acid positions that may be
subject to selective pressure in MAb-treated subjects compared to
placebo treated subjects. For each position, we performed a chi-
square test to quantify the change in the amino-acid distributions
between day 0 and the day of rebound, using the day 0 distribution
as the expected frequencies and the distribution at rebound as the
observed frequencies. A larger chi-square value would therefore
correspond to a greater deviation from the day 0 distribution.
We performed this analysis on all 621 sequenced positions
across 6 MBL-HCV1-treated and 4 placebo-treated subjects;
subject J in the placebo group could not be analyzed due to low
post-rebound viral titers (,10,000 IU/ml). The degree of
variation at each amino acid position post-viral rebound was
ranked by comparing the difference in the average chi-square
values among the MAb-treated subjects and the average chi-
square values among the placebo-treated subjects. The heatmap in
Figure 3 shows the normalized variations (absolute difference
between each position’s chi-square statistic value and the median
chi-square value across all positions for the patient) for the 15 most
significant amino acid positions. Owing to very high coverage and
the sensitivity of this method to coverage, we found that many
positions changed significantly between day 0 and the day of
rebound. However, the difference in average magnitudes of the
amino acid variation between MAb- and placebo-treated subjects
at position 415 was 10 times higher than the next highest position,
417 (Figure 3), which highlights the importance of position 415 in
antibody evasion. Moreover, the heatmap shows that positions 415
and 417 are highly significant across all six MAb-treated subjects
and the other positions were only highly significant among subsets
of patients. Changes at these other positions co-occur with
alterations at position 417 in a subset of MAb-treated subjects
(A and D) and could either interfere with MBL-HCV1 binding
through an indirect or allosteric effect or could potentially
represent compensatory changes which enhance infectivity of the
RAVs. Given that the N417S mutation confers full resistance to
MBL-HCV1 neutralization [7], it is unlikely that mutations
outside of the MBL-HCV1 epitope in conjunction with N417S
provide additional resistance to neutralization. These changes may
enhance fitness of the N417S variant or they may be fortuitous.
The recently published crystal structure of the HCV E2 core [9]
permitted us to examine these positions in greater detail with
respect to the MBL-HCV1 epitope and the tertiary structure of E2
(Table S2). All of the positions were relatively distant (.18 A˚)
from residues 421–423 of the epitope (residues 412–420 were
disordered in the E2 core structure), and on the opposite side of
the E2 core, confirming as noted above that impact on MAb
binding, if any, would not be via direct interference. Though they
have varying degrees of surface exposure in the E2 core structure,
the relatively conservative nature of the amino acid changes before
and after MAb treatment, as well as the lack of E1 and remainder
of the E2 protein in the structure, makes their functional
importance in the context of MAb resistance difficult to assess
without additional data.
Discussion
Treatment at the time of liver transplantation presents a
potential opportunity for clearance of hepatitis C infection, given
that the primary source of infectious virions is the patient’s infected
liver [3]. Nearly all HCV-infected patients experience a substantial
drop in circulating viral load at the time the diseased liver is
removed, only to have viral titers increase rapidly as the donor
liver becomes productively infected [2,3]. An immunoprophylactic
strategy to neutralize circulating virions with HCV-specific
antibody therapy could exploit this opportunity and protect the
allograft in the peri-transplantation period. Human monoclonal
antibody MBL-HCV1 provided potent suppression and selective
pressure on HCV during the early post-transplant period in a
randomized, placebo-controlled trial [8]. Viral load was sup-
pressed in 6 of 6 MAb-treated subjects for time periods ranging
from 7 to 28 days, though the virus eventually rebounded with a
population dominated by variants with alterations at positions 415
or 417 of the E2 envelope glycoprotein determined by Sanger
sequencing [8]. Alterations at these positions have previously been
shown to be the main route(s) of escape from MBL-HCV1
neutralization in vitro [6] as well as in vivo in chimpanzees [7].
We developed a high-throughput sequencing methodology to
improve the sensitivity to detect low frequency viral strains and
further investigate the presence of MAb resistance-associated
variants before transplant as well as the development of MAb-
escape variants in the peri-transplant and early post-transplant
period. Evaluation of rebounding virus load by high-throughput
sequencing in MAb-treated subjects identified the same population
of escape variants as seen by Sanger sequencing for 5 of the 6
MAb-treated subjects [8]. For Subject C, only high-throughput
sequencing detected the N417S variant at 12.7% on day 14, the
earliest day rebound was detected. This variant later dominated
the viral population when a sample from Day 56 was subject to
Sanger sequencing.
High-throughput sequencing was also used to evaluate the pre-
transplant viral population in the study subjects. Sanger sequenc-
ing of pre-treatment serum samples from subjects in the MAb
cohort did not detect any of the resistance-associated variants
present at the time of viral rebound [8]. There was a single subject
in the placebo group (Subject J) whose dominant viral species was
an N417S epitope variant, both pre- and post-transplant. With a
sensitivity threshold of 0.5–3.5%, we were unable to detect any
additional MAb-resistance associated variants before transplanta-
tion. In studies of drugs inhibiting the HCV NS3 protease, the
frequency of patients with pre-existing NS3 resistance associated
variants was 12% by deep sequencing (0.25% assay cutoff) and
3.5% by Sanger sequencing (20% cutoff) [10,11]. However, when
treated with telaprevir in combination with interferon-a and
ribavirin, individuals with resistance-associated variants detectable
Figure 1. Changes in viral loads and epitope sequence distributions upon MBL-HCV1 antibody administration. A–F: Epitope
distributions for subjects A, B, C, D, E and F respectively. X axis represents time point in days, 0 denoting pre-transplant baseline sample. Note the
depletion of wild-type sequence in all patients and the emergence of resistant epitope sequences (see proportions in left Y axis), in conjunction with
viral rebound (right Y axis). Positions 415 and 417 are highlighted in blue in the legend. G: Summary of antibody-resistant mutations in epitope
sequences, assuming maximum parsimony. Glycosylation motifs are highlighted in orange.
doi:10.1371/journal.pone.0100325.g001
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at baseline by Sanger sequencing had similar rates of sustained
virologic response as individuals without detectable baseline
resistance-associated variants [10]. As resistance-associated vari-
ants to MBL-HCV1 were not detectable in MAb-treated subjects
prior to therapy, we are unable to evaluate the virologic response
in subjects with pre-existing variation in E1/E2 that could
potentially impact neutralization. Given the time required for
three of the six subjects to present with viral rebound (.14 days),
either RAV were not present in the viral population at the time of
treatment or any RAV present prior to treatment required
additional mutations to acquire replication fitness in at a minimum
these three treated subjects. Given the rapid replication rate of the
Hepatitis C virus within in the host, it is unlikely that the
differences in time to viral rebound observed within the MAb
cohort were a result of varying levels of pre-existing resistance-
associated variants prior to transplantation.
We attempted to evaluate the evolution of the viral population
in the early post-transplant period; however, our evaluations were
severely limited by the low HCV viral load in these samples. This
effect was most pronounced in the MAb-treated group, where
serum samples with HCV RNA concentrations ,1000 IU/ml
were unable to be successfully amplified. In addition, the biologic
reproducibility of sequencing results from samples containing
HCV RNA serum titers between 1000–10,000 IU/ml was poor.
Although deep sequencing significantly increases the sensitivity
and resolution of sequencing in clinical samples, the ability to draw
conclusions from samples with low viral concentrations remains
limited by the starting amount of viral template. In low titer
Figure 2. Changes in viral loads and epitope sequence distributions in placebo subjects. A–E: Epitope distributions for subjects G, H, I, J
and K respectively. X axis represents time point in days, 0 denoting pre-transplant baseline sample. Left Y axis represents proportion of reads with a
particular sequence and right Y axis represents viral loads across time points (X axis). Subject J did not have viral titers $10,000 IU/ml by day 21;
therefore analysis of post-transplant epitope sequence distributions could not be performed.
doi:10.1371/journal.pone.0100325.g002
Figure 3. Positions in E1/E2 sequence that show the most significant changes in response to antibody treatment. Left: Median-shifted
chi-square statistic values of the top 15 amino acid positions across E1 and E2 that show the most difference in average chi-square statistic between
MBL-HCV1- and placebo-treated subjects. Placebo subject J was unable to be analyzed due to post-rebound viral titers ,10,000 IU/ml. The chi-
square statistic quantifies changes in amino acid distributions between day 0 and day of rebound for each subject in each position across the
genome. A higher statistic represents a larger change in the amino acid distribution (darker red in heatmap). Positions labeled in green are those
within the MBL-HCV1 epitope. Positions labeled in blue are known to participate in CD81 binding. Positions in pink belong to the E1 sequence.
Right: Differences in mean chi-square statistic between MBL-HCV1-treated and placebo patients. Note that change in position 415 is most significant
being 10-fold higher than the second-ranked position 417.
doi:10.1371/journal.pone.0100325.g003
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samples, each viral template constitutes a larger percentage of the
total sample and small variations in amplification efficiency can
yield marked changes in final frequency [12].
All of the MBL-HCV1-treated subjects had an alteration at
amino acid positions 415 (N415D, N415K, N415S) or 417
(N417S) of the E2 glycoprotein at the time of post-transplant viral
rebound. Sequence analysis of the 412–423 epitope in its entirety
revealed that the 415 and 417 changes were never observed in the
same virus. Interestingly, the N417S mutation mostly likely
affected neutralization through its impact on the 415 position,
by shifting the N-X-S glycosylation site to the asparagine at
position 415. Recent in vitro studies have also confirmed this in
vivo observation. Pantua et al. [13] synthesized the N417S variant
of E2, observed decreased ability to neutralize virus in vitro with
epitope I-directed antibodies, and confirmed glycosylation of the
415 asparagine by mass spectroscopy. The change at position 415
also appeared to be sufficient to confer resistance, in an otherwise
replication competent virus, as there were no other sites on the
E1/E2 glycoprotein that were consistently mutated at the time of
rebound in multiple subjects. This is supported by the exposed
‘‘flap-like’’ structure of the MBL-HCV1 epitope [14] that is
apparently not embedded in the E2 core structure [9], reducing
the likelihood of interaction with other residues at least within the
main core structure (positions 412–645).
There are both pre-clinical as well as emerging clinical evidence
to suggest that addition of a second antiviral agent with a discrete
mechanism of action can impair the development of resistance.
The addition of the licensed HCV NS3 protease inhibitor
telaprevir to an antibody binding the E2 412–423 epitope in vitro
led to a synergistic negative effect on viral replication and
suppressed the emergence of resistance to both agents [13]. Given
that the baseline frequency of HCV variants with resistance
associated mutations in E2 412–423 appears to be low and that
post-transplant viral rebound is delayed until after day 7, antibody-
based peri-transplant treatment could provide a safe, well-
tolerated therapy that can be started at the time of transplant
surgery and allow a window of a few days for a small molecule
antiviral agent targeting a different stage of the viral life cycle to be
added once the patient has stabilized and graft function is
established. Such combination therapy holds the potential to
eliminate the hepatitis C virus before a chronic infection can be
established in the newly transplanted liver.
Materials and Methods
Ethics Statement
The clinical trial was registered at ClinicalTrials.gov (Registra-
tion number NCT01121185). Details of the trial are also detailed
in Chung et al [8]. The protocol was approved by each study site’s
institutional review board and conducted in accordance with
Good Clinical Practice guidelines set by the International
Conference on Harmonization. All subjects provided written
informed consent. The following is the list of IRBs of the study
sites that conducted the clinical trials.
N Yale-New Haven Hospital IRB, New Haven, Connecticut,
United States, 06504
N Beth Israel Deaconess Medical Center IRB, Boston, Massa-
chusetts, United States, 02215
N Massachusetts General Hospital IRB, Boston, Massachusetts,
United States, 02114
N Lahey Clinic IRB, Burlington, Massachusetts, United States,
01805
N Henry Ford Health System IRB, Detroit, Michigan, United
States, 48202
N Mount Sinai Hospital IRB, New York, New York, United
States, 10029
N Cleveland Clinic Foundation IRB, Cleveland, Ohio, United
States, 44195
N Methodist Healthcare Foundation IRB, Memphis, Tennessee,
United States, 38104
Collection of Serum Samples for Viral Sequence Analyses
Serum samples for HCV sequence analyses were obtained at
protocol-specified timepoints as part of a randomized, double-
blind, placebo-controlled trial of MBL-HCV1 treatment in liver
transplant patients [8]. Eleven subjects with HCV genotype 1a
infection were enrolled; six subjects received 11 study infusions of
MBL-HCV1 (50 mg/kg each) and five subjects received 11
infusions of placebo (0.9% sodium chloride, starting right before
transplant surgery and continuing for 14 days. Serum samples for
assessment of HCV RNA titers and for viral sequence analyses
were obtained prior to transplant, daily for the first post-transplant
week, and weekly through day 5662 post-transplantation. Serum
HCV RNA levels were measured at ICON Central Laboratories
(Farmingdale, NY) using the COBAS Ampliprep/COBAS Taq-
Man HCV Test (Roche Molecular Diagnostics) as previously
described [8].
E1/E2 Amplification and High-throughput Sequencing
Viral RNA was extracted from 1 ml of human sera using the
QIAamp viral RNA mini kit (Qiagen) as described by the
manufacturer to a final volume of 240 microliters. Three
microliters of viral RNA in six independent reactions for each
sample was amplified using the Superscript III One-Step RT-PCR
system with Platinum Taq (Invitrogen). For specific amplification,
a forward oligonucleotide containing a HindIII restriction site (59-
gct tag caa gct tCG CCG ACC TCA TGG GGT ACA TAC
CGC TCG-39) targeting the gene encoding core, upstream of the
E1 gene and a reverse oligonucleotide containing an XbaI
restriction site (59-cgc ttg ctc tag aCG AGG TT CTC CAA
AGC CGC CTC CGC TTG G-39) annealing to the 39 end of E2
were designed. RNA was reverse transcribed and DNA amplified
for 30–40 cycles. RT-PCR resulted in an amplicon approximately
1890 bp in size representing the entire E1/E2 coding region.
For serum samples obtained at baseline or following 2 log10 viral
rebound, the six independent reactions for each serum sample
were pooled, resolved on agarose gels and gel purified. A portion
of the sample was cloned into pcDNA3.1 using HindIII/XbaI and
conventional Sanger sequencing was performed on 8–20 unique
clones. Approximately 1–5 micrograms of RT-PCR product was
sheared using a Covaris S-series SonoLab Single sonicator to
obtain DNA fragments near 225 bp in size. The 59 and 39 ends of
the sheared DNA were repaired and blunted using the End-It
DNA End-Repair Kit (Epicentre). Blunted DNA was A-tailed
using the Exo-minus Klenow kit (Epicentre). Illumina paired-end
adapters containing 5-mer barcodes were ligated to the A-tailed
DNA and the reaction products were resolved on 2% agarose gels.
Adaptered material in the range of 200–250 bp was gel purified
and amplified (18 cycles) with Platinum Pfx (Invitrogen) and
Illumina paired-end primers 1.01 and 2.01. Amplified material
was purified using a QiaQuick PCR clean up kit (Qiagen). Purified
material was assessed for concentration and library size distribu-
tion using an Agilent 2100 Bioanalyzer G2939A with the Agilent
Bioanalyzer High Sensitivity DNA Kit.
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For serum samples obtained prior to 2 log10 post-transplant viral
rebound, a nested PCR was employed using subject-specific
primers designed based on Sanger sequencing results of pre-
transplant and post-rebound timepoints. Briefly, sequences
upstream of the E1 gene were analyzed for each individual
subject and a region with no nucleotide variability (pre-transplant
or post-viral rebound) was selected for primer design. The reverse
primer was the same as used in the One-Step RT-PCR and the
forward primers were as follows: Subject A, 59-gct tag caa gct tGC
TGC CAG GGC CCT GGC GCA TGG C-39; Subject B, 59-gct
tag caa gct tGG CGT CCG GGT TCT GGA AGA CGG CGT
G-39; Subject C, 59-gct tag caa gct tCC CTG GCG CAC GGC
GTC CGG GTT C-39, Subject F, 59-gct tag caa gct tCT GGC
GCA TGG CGT CCG GGT CCT GG-39. Reamplified products
were prepared for high-throughput sequencing as described above.
High-Throughput Sequence Acquisition and Data
Analysis
All samples were sequenced using an Illumina HiSeq 2000
instrument to yield 100-nucleotide paired-end reads. Table S3
provides detailed statistics on the sequencing datasets of all
samples. Sequence quality was assessed using the FastQC software
{http://www.bioinformatics.babraham.ac.uk/projects/fastqc/} and
samples with inadequate quality were re-sequenced. In order to
maintain comparable sequencing accuracies between samples, only
reads with a quality score of 28 or higher for the first 50 bases were
included in the analyses. These reads were mapped to a database of
581 E1/E2 HCV1 sequences obtained by Sanger sequencing from
27 HCV-infected individuals, including the 11 subjects in the current
protocol. The BWA software [15] was used for read mapping,
allowing a maximum of 5 mismatches per read. Datasets with an
average fold-coverage of less than 40,000 reads per base were
discarded. If multiple sequencing runs of the same sample passed the
above criterion, the dataset with the greatest fold coverage was used
for downstream analysis.
Sequencing error for each dataset was estimated by computing
the mean and standard deviation of error per base (percentage of
reads with incorrect base calls) in the invariant 39-end primer
region. The detection threshold for each sample was defined as the
mean plus one standard deviation of the error rate, i.e., a
nucleotide variant is considered to be present in a sample if its
frequency is higher than the detection threshold. The sensitivity
thresholds ranged from 0.5–3.5% across the datasets (Table S1).
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primer sequences.
(DOCX)
Table S2 Significant amino acid changes outside of the
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